From basic studies to clinical application: Advances in novel oncogene ATAD2 and tumors / 肿瘤

ABSTRACT

AT Pase family, AAA domain containing 2 (ATAD2) is a newly uncovered oncogene playing an important role in occurrence and development of prostate cancer, breast cancer and other human malignancies. It is a coactivator of a variety of transcription factors, and it can also modulate genes through epigenetic modifications, resulting in overexpression of its downstream oncogenes, and in turn changing the phenotypes of tumor cells; what's more, the expression of ATAD2 is associated with histological grade of cancer, metastasis, disease recurrence and the survival, indicating that it can be used as a molecular marker for prognosis of cancer and has remarkable value in clinical application. Furthermore, ATAD2 contains bromodomain (BRD) and also functions as cellular activity-associated ATPase, which means that ATAD2 may be a potential target for drug therapy. This review summarizes the recent findings and discusses the prospect of this field.